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The anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitidies (AAV) are 
characterised by autoantibodies, directed against myeloperoxidase (MPO) or 
proteinase 3 (PR3). Although antibodies are considered the principal effector 
molecules of the autoreactive B cells, B cells can also act to suppress harmful 
autoimmune responses. B cell deficiency in mice can result in exacerbated 
autoimmune responses [Mauri et al., 2003; Fillatreau et al., 2002; Mizoguchi et al., 
1997]. Protection has been attributed to a subset of B cells, which produce IL10. 
These B regulatory cells, express high levels of CD5, CD10, CD38, CD24 and 
CD1d surface antigens in man and are functionally impaired in SLE [Blair et al., 
2010]. The balance of B cell subpopulations in AAV remains unknown; the aim of 
this study was to determine whether there was any difference in the relative 
frequency of B cell subsets in AAV compared to controls. 
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AAV patients were treated with 
a combination of therapies, 
summarised in figure 1. All 
transplant recipients were  on 
combined AZA/MMF and 
FK/CsA therapy (100%).  
Healthy controls and tolerant 
patients received no treatment. 
 
 
Abbreviations: predinsolone (PRED), tacrolimus (FK), Ciclosporin A (CsA) , methotrexate (MTX), 
azathioprine (AZA), mycophenolate (MMF),  cyclophosphamide (CYC), mycophenolic mofetil (MMF) and 
rituximab (RTX).  
 
Methods 
Patients and controls 
Introduction 
Table 1. Demographics and ANCA-specificity.  
Mononuclear cells were isolated from peripheral blood by density gradient 
centrifugation on Lymphoprep (Axis-Shield, Dundee, UK); viability was 95% or 
greater, assessed by trypan blue exclusion (Invitrogen, Paisley, UK).  
Flow cytometry was conducted with: CD19 PE-Cy7 (HIB19), CD24 PE (eBioSN3) 
and CD38 FITC (HIT2) antibodies (eBioscience, Hatfield, UK). A healthy control 
was included in each analytical run and staining conducted, alongside isotype and 
single-colour compensation controls. Data was acquired on an LSRFortessa 
instrument (BD Biosciences, Oxford, UK) and analysis conducted with FlowJo 
software (Treestar, Inc., San Carlos, CA).  
Statistical analysis was performed with GraphPad Prism (GraphPad Software, San 
Diego, CA) using one-way ANOVA and student’s unpaired, two-tailed t-test. 
CD19 PE-Cy7 
CD38 FITC 
Results 
The combination of CD19, CD24 and CD38 antibodies, permits definition of 
regulatory (CD19+CD38hiCD24hi), memory (CD19+CD24hiCD38−) and mature 
(CD19+CD38intCD24int) B cell subsets [Carsetti et al, 2004; Sims et al, 2005]. 
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  Regulatory B cells Memory B cells Mature B cells Memory:Regulatory 
  frequency (%) frequency (%) frequency (%) cell ratio  
AAV - All patients 3.33 ± 0.42  20.79 ± 1.95 75.89 ± 1.85  22.37 ± 5.42 
 AAV- Tolerant  4.24 ± 0.66  14.18 ± 2.59  81.58 ± 2.79 6.37 ± 2.43 
           Active disease  4.61 ± 0.82  14.94 ± 1.18 80.46 ± 1.20 5.06 ± 0.76 
           Remission 1.92 ± 0.34 27.90 ± 3.54 70.18 ± 3.47 42.47 ± 10.33 
Transplant recipients 5.05 ± 0.91  19.06 ± 3.29  75.89 ± 3.09 12.47 ± 6.59 
Healthy controls 4.02 ± 0.38 38.69 ± 5.14  57.29 ± 5.17 10.26 ± 1.66 
1 way ANOVA 0.0042** < 0.0001**** ***0.001 0.0011** 
Table 2. Results from B cell immunophenotyping 
Figure 3. Representative B cell plots, paired contour and dot plots  
Tolerant AAV Remission AAV Active AAV Prior RTX therapy 
Figure 2. Schematic of gating strategy and sample data from a healthy control  
To confirm suppressive ability of B regulatory cells, co-cultures were set up at a ratio of 1:4 with   
untouched CD4+ CD25- T cells (B regs were isolated by FACS sort and T cells were isolated using MS 
columns and microbeads, Miltenyi Biotech, Surrey, UK).  These studies showed reduced  proliferation 
in  T:B co-culture, compared to T cells alone ; there was 33% less division of the CD4 cells as assessed 
by CFSE dilution at 72 hours (CD4 clone RPA-T4, Biolegend, San Diego; CFSE, Invitrogen, Paisley, UK). 
This was accompanied  by subsequent reduction in T cell differentiation at 5 days; 27% fewer TNF-
alpha positive CD4 cells detected (eBioscience clone,  MAb11). 
Figure 4. Summary of  flow cytometry data, SEM and statistical significance  
  shown (unpaired, two-tailed Student’s t-test) 
Graphs (a-c) show frequencies of B cell subsets, expressed as a percentage of total CD19+ events. 
Significant differences were found  in the proportion of memory and mature B cells in active, tolerant 
and transplant patients, compared to healthy controls (not shown). B cell frequencies also differed 
according to disease activity in AAV; there were more memory B cells and fewer regulatory and mature 
B cells in remission. Ratio of memory to regulatory cells was calculated by  dividing the number of  
cells in the memory cell gate by the number in regulatory B cell gate M:R(n). This ratio differed 
according to disease activity in AAV and was lower in patients with active disease, compared to healthy 
controls; graph (d).  
a) b) 
d) c) 
REGULATORY B CELLS IN ANCA ASSOCIATED VASCULITIS:  
THEIR ROLE IN RESTORING IMMUNE TOLERANCE 
SK Todd1, RJ Pepper1, A Tanna1, C Mauri2 ,  AD Salama1  
Additional flow cytometry staining showed 
that the B regulatory cells were CD5 high and 
B memory cells CD27 positive; confirming 
phenotype assigned by CD19, CD24 and 
CD38 labelling (eBioscience, clones UCHT2 
and O323). 
Initial gating for lymphocytes, 
based on intrinsic physical 
properties (forward and side 
scatter); followed by selection of B 
cells, by expression of CD19 cell 
surface antigen. 
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Plots show variation in the 
frequency of B cell 
subpopulations in the AAV 
patient groups.  
 
The image on the far right hand 
side shows enrichment of B 
regulatory cells following 
rituximab treatment, as 
previously described 
[Palanichamy et al, 2009]. 
    Gender                  Age   Autoantibody specificity 
  N M F Mean ±SEM Range PR3 MPO Atypical  None 
AAV - All patients 48 25 23 59.3 ± 2.4  17-85 25 18 1 4 
 AAV- Tolerant  6 5 1 67.3 ± 6.8  46-85 1 4 0 1 
           Active disease  20 12 8 53.0 ± 2.9   32-72 12 5 1 2 
           Remission 22 8 14 62.8 ± 3.9  17-85 12 9 0 1 
Transplant recipients 11 4 7 62.3 ± 2.6   49-75 0 0 0 0 
Healthy controls 9 6 3 40.9 ± 3.7  21-57 0 0 0 0 
Figure 5. Suppressive ability of CD19+CD38hiCD24hipopulation 
Remission AAV patients have fewer B regulatory cells than active or tolerant 
patients. This is not likely to be solely due to immunosuppression as transplant 
recipients have a greater immunosuppressive load and higher frequency of B 
regulatory cells. 
The B regulatory cells characterized in this study by high expression of CD24 and 
CD24, are functionally suppressive, inhibiting T cell proliferation and cytokine 
production. Further investigation of B regulatory function in tolerant and remission 
patients is currently underway. 
B regulatory cells are restored in those AAV patients who regain immunological 
tolerance. Harnessing B regulatory cells may be a novel therapeutic strategy for 
relapsing remitting AAV.  
 
 
 
 
Conclusions 
T cells alone B :T  
CFSE dilution in CD4 cells 
The AAV cohort comprised patients with active disease; those in remission and 
patients who had regained immune tolerance. Tolerant patients were defined as 
those with a history of active AAV, who subsequently became autoantibody negative 
and remained free from pathology after withdrawal of immunosuppression 
(minimum of 2 years). B cell frequency was assessed in AAV cohorts as well as 
healthy and immunosuppressed controls (renal transplant recipients). 
Figure 1. AAV treatment  
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